Precision & Science
Driven by AI
From specific cancer gene panels to optimal drug response predictions and profiles, it’s precision oncology workflow in real time.
Precisely Match Drugs to Treatment Plans
Our flagship breast cancer panel screens 68 critical breast cancer genes, along with select introns and microsatellite instability hotspots. This provides unmatched insights into the tumor, revealing treatment opportunities that broader pan-cancer panels often overlook.
GeneSilico offers a specific cancer panel with a curated set of genes relevant to treat a specific cancer type that focus on key homologous recombination pair (HRR) and pharmacogenomics genes, aligned with 32 microsatellite instability hotspots resulting in precise matching of drugs to targets.
Case Study Profile
In August 2014, a 57-year-old woman was diagnosed with invasive ductal carcinoma of the breast (Grade II). The tumor was hormone receptor-positive (ER+, PR+), HER2-negative, with a moderate Ki67 proliferation index (10%). Alongside her cancer diagnosis, the patient also had a comorbidity (hypertension).
Multi-Omic Drug Response Prediction
Our advanced genetic science pinpoints the most aggressive cancer subclones within a tumor, identifying those with the highest risk to guide optimal drug response predictions for individual patients.
Our proprietary CellMath technology leverages both single-cell and bulk omics data to model tumors in a vector space. This allows for precise algebraic analysis of subclonal phenotypic signatures, enabling oncologists to target the most aggressive cancer cell clones with focused therapeutic interventions.
Clinical Validation at Speed and Scale
GeneSilico continually integrates high-throughput screening data with matched tumor omics and drug response profiles, enhancing its Precision Oncology workflows in real-time.
Our comprehensive data lake includes hundreds of approved and investigational cancer drugs, along with omics profiles from cell lines, patient tumors, and xenografts.
AI models are continuously refined by oncologists through transfer and reinforcement learning, improving accuracy and adaptability during clinical practice and trials.
Multiomic Data Stack for Deep Precision Oncology
GeneSilico’s Multiomic Data Stack for Deep Precision Oncology represents an approach which enables an in-depth, multi-factor analysis of tumors by combining several critical data layers (mutations, copy number variations, gene expression, DNA methylation, microRNA profiles, RPPA, and clinical data). Our platform provides a holistic view of each cancer's molecular landscape, thereby widening patient-specific biomarker search and therapy pairing. Multi-omics datasets, which are central to our innovation, offer significant potential value in simulating drug response at the patient level.
.jpg)
Transform Your Practice Today
Book a demo to explore how gSage can revolutionize your cancer care approach, offering AI-driven insights and personalized treatment solutions that enhance patient outcomes.
.jpg)